Alnylam Pharmaceuticals Inc (ALNY)

Precedente Chiudi:

$147.36

Aprire:

$146.07

Volume 24 ore:

138.48K

Capitalizzazione di mercato:

$18.50B

Reddito:

$1.83B

Utile/perdita netta:

$-440.24M

Rapporto P/E:

-35.28

EPS:

-4.14

Flusso di cassa netto:

$41.95M

1 W Prestazione:

+0.11%

1M Prestazione:

-2.15%

6M Prestazione:

-3.42%

1 anno Prestazione:

-26.59%

Intervallo 1D:

$145.42

$148.05

Portata 52W:

$141.97

$218.88

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Nome

Alnylam Pharmaceuticals Inc

Settore

Healthcare (1193)

Industria

Biotechnology (687)

Telefono

617-551-8200

Indirizzo

300 Third Street, 3rd Floor, Cambridge, MA

Dipendente

1,000

Cinguettio

@alnylam

Prossima data di guadagno

2024-05-16

Ultimi documenti SEC

ALNY's Discussions on Twitter

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-02-16	Downgrade	Goldman	Buy → Neutral
2024-02-15	Iniziato	Wolfe Research	Peer Perform
2023-12-08	Iniziato	Wells Fargo	Equal Weight
2023-10-11	Downgrade	Oppenheimer	Outperform → Perform
2023-09-29	Iniziato	Raymond James	Outperform
2023-05-05	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2023-04-26	Iniziato	SMBC Nikko	Neutral
2023-03-21	Iniziato	Bernstein	Outperform
2023-01-18	Iniziato	Canaccord Genuity	Buy
2022-09-09	Ripresa	Morgan Stanley	Equal-Weight
2022-07-13	Iniziato	Cantor Fitzgerald	Neutral
2022-06-27	Downgrade	Guggenheim	Buy → Neutral
2022-06-07	Iniziato	William Blair	Outperform
2022-04-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2022-03-01	Iniziato	Citigroup	Buy
2022-02-03	Aggiornamento	Guggenheim	Neutral → Buy
2022-01-03	Aggiornamento	Piper Sandler	Neutral → Overweight
2021-11-22	Aggiornamento	Goldman	Neutral → Buy
2021-11-22	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2021-11-01	Aggiornamento	Oppenheimer	Perform → Outperform
2021-10-04	Aggiornamento	UBS	Neutral → Buy
2021-08-04	Downgrade	Piper Sandler	Overweight → Neutral
2021-02-22	Downgrade	Guggenheim	Buy → Neutral
2021-02-12	Downgrade	Citigroup	Buy → Neutral
2021-02-12	Reiterato	H.C. Wainwright	Buy
2021-01-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
2020-09-30	Ripresa	Berenberg	Hold
2020-09-08	Iniziato	Citigroup	Buy
2020-08-11	Downgrade	Oppenheimer	Outperform → Perform
2020-05-13	Iniziato	RBC Capital Mkts	Sector Perform
2020-05-07	Downgrade	JP Morgan	Overweight → Neutral
2020-04-24	Ripresa	Evercore ISI	Outperform
2020-03-19	Iniziato	Berenberg	Buy
2019-12-19	Reiterato	Chardan Capital Markets	Buy
2019-11-20	Iniziato	Oppenheimer	Outperform
2019-11-13	Iniziato	BofA/Merrill	Buy
2019-05-23	Ripresa	Goldman	Neutral
2019-04-12	Iniziato	Evercore ISI	Outperform
2019-03-06	Aggiornamento	Evercore ISI	In-line → Outperform
2019-03-05	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2019-01-23	Iniziato	UBS	Neutral
2018-10-01	Iniziato	Cantor Fitzgerald	Overweight
2018-08-13	Reiterato	Stifel	Buy
2018-08-07	Aggiornamento	Stifel	Hold → Buy
2018-05-04	Reiterato	Stifel	Hold
2018-03-28	Iniziato	Evercore ISI	In-line

Mostra tutto

Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie

Gear Up for Alnylam (ALNY) Q1 Earnings: Wall Street Estimates for Key Metrics

Zacks Investment Research

Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?

Zacks Investment Research

What's in the Cards for Amgen (AMGN) This Earnings Season?

Zacks Investment Research

Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?

Zacks Investment Research

Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?

Zacks Investment Research

Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research

Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari

Alnylam Pharmaceuticals Inc (ALNY) Reddito 2024

Alnylam Pharmaceuticals Inc (ALNY) Reddito netto 2024

Alnylam Pharmaceuticals Inc (ALNY) Flusso di cassa 2024

Alnylam Pharmaceuticals Inc (ALNY) Utile per azione 2024

Alnylam Pharmaceuticals Inc Azioni (ALNY) insider trading